Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy
- Details
- Category: Amgen

Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent
- Details
- Category: Abbott

Lilly Reports on Outcome of Phase III Study of Arzoxifene
- Details
- Category: Eli Lilly and Company

Novartis drug Femara® is superior to tamoxifen after breast cancer surgery
- Details
- Category: Novartis

Nycomed reports sustained momentum in second quarter 2009
- Details
- Category: Nycomed

Pfizer And Private Access Announce Plans To Develop Online Community To Accelerate Clinical Research
- Details
- Category: Pfizer

US FDA approves Extavia® - the first in a new portfolio of planned MS therapies from Novartis
- Details
- Category: Novartis

More Pharma News ...
- Orphan Drug Designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS)
- Positive top-line results from a Phase 3 trial evaluating Vectibix (panitumumab)
- Pandemic (H1N1) 2009 influenza update
- Sanofi Pasteur submits supplemental application for A(H1N1) pandemic vaccine to U.S. FDA
- Forest Laboratories and AstraZeneca to Co-Develop and Commercialize a Next Generation Anti-Infective
- Studies Highlight Potential New Option in the Treatment of Bone Loss
- Sandoz launches first generic version of Prograf® capsules